Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways.
about
Autoregulation and heterogeneity in expression of human Cripto-1Cripto-1 overexpression is involved in the tumorigenesis of nasopharyngeal carcinoma.Significance and relationship between Cripto-1 and p-STAT3 expression in gastric cancer and precancerous lesions.CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.Targeting the embryonic gene Cripto-1 in cancer and beyond.Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges.Age-Dependent Association between Protein Expression of the Embryonic Stem Cell Marker Cripto-1 and Survival of Glioblastoma Patients.Human Cripto-1 as a target for a cancer vaccine: WO2008040759.Immunotherapy: a useful strategy to help combat multidrug resistance.Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition.Galloyl benzamide-based compounds modulating tumour necrosis factor α-stimulated c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signalling pathways.Effect of gamma-synuclein silencing on apoptotic pathways in retinal ganglion cells.
P2860
Q28543279-86865C6D-31FB-402F-B45F-A7A10E08B9BEQ33500375-BA6C9312-DEA1-44CC-A0F7-FDE5AFA543E0Q33629428-E88E4255-8052-42FD-B4BB-12710B2F6679Q33808203-2F213C4A-88C8-45C5-A188-8CAE45402BD9Q34688767-21ADCDC9-45C3-47A8-B2F4-FA9503A296A8Q35136562-146F77C2-8E80-4966-98A7-BA32DA4DB0F0Q37073702-C429C2F2-3CE3-4EE9-BFEC-05E48D27E4CCQ37076348-19335D10-EC19-40D5-9745-CD9224002843Q37474393-B2DEC5D8-7EBE-4607-970F-991744C49034Q37481287-A0B4E5E2-1DAF-4ADE-B734-C755755A691AQ38000768-921D8420-718D-4EDC-B729-3BEE1B8797CBQ38055067-5A625170-C257-4103-9CFE-449C4F1A4B6BQ38242892-5B327283-D791-497C-857A-EB74B274B2BBQ38995223-451C6CFA-7CB3-402D-95C7-936FC5E941FFQ43225121-BD9F7F23-280E-4F9B-85A3-0D4509D6A52E
P2860
Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Anti-Cripto Mab inhibit tumour ...... K/SAPK and bad death pathways.
@ast
Anti-Cripto Mab inhibit tumour ...... K/SAPK and bad death pathways.
@en
type
label
Anti-Cripto Mab inhibit tumour ...... K/SAPK and bad death pathways.
@ast
Anti-Cripto Mab inhibit tumour ...... K/SAPK and bad death pathways.
@en
prefLabel
Anti-Cripto Mab inhibit tumour ...... K/SAPK and bad death pathways.
@ast
Anti-Cripto Mab inhibit tumour ...... K/SAPK and bad death pathways.
@en
P2093
P2860
P356
P1476
Anti-Cripto Mab inhibit tumour ...... K/SAPK and bad death pathways.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603641
P407
P577
2007-03-06T00:00:00Z
P5875
P6179
1001421892